» Articles » PMID: 34759282

De-escalation Antibiotic Therapy Alleviates Organ Injury Through Modulation of NETs Formation During Sepsis

Overview
Date 2021 Nov 11
PMID 34759282
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Empiric broad-spectrum antimicrobials therapy is suggested to be started immediately for sepsis patients. Empiric antimicrobial therapy should be narrowed once pathogen identification and sensitivities are established. However, the detailed mechanisms of de-escalation strategy are still unclear. Here we hypothesized neutrophil extracellular traps (NETs) played an essential role and de-escalation strategy might alleviate organs injury through regulation of NETs formation in sepsis. We evaluated the effect of imipenem and ceftriaxone on NETs formation in vitro and examined the role of reactive oxygen species (ROS). Next, we designed de-escalation and escalation strategy in cecum ligation and puncture (CLP) models. Organ injury, inflammatory cytokines, NETs levels were compared and evaluated. In CLP models, de-escalation therapy resulted in an increased serum MPO-DNA level during the early stage and decreased MPO-DNA level during late stage, which exerted the reverse effects in escalation therapy. Inflammatory response and organ injury exacerbated when eliminated NETs with DNAse I during the early stage of sepsis (p < 0.01). Histopathological analysis showed decreased injury in lung, liver, and intestine in de-escalation therapy compared with escalation therapy (p < 0.01). De-escalation therapy results in the highest 6-day survival rate compared with the control group (p < 0.01), however, no significant difference was found between de-escalation and escalation group (p = 0.051). The in vitro study showed that the imipenem could promote, while the ceftriaxone could inhibit the formation of NETs in PMA-activated PMNs through a ROS-dependent manner. We firstly demonstrate that de-escalation, not escalation, therapy reduces organ injury, decreases inflammatory response by promoting NETs formation in the early stage, and inhibiting NETs formation in the late stage of sepsis.

Citing Articles

Role and Therapeutic Targeting Strategies of Neutrophil Extracellular Traps in Inflammation.

Li X, Xiao S, Filipczak N, Yalamarty S, Shang H, Zhang J Int J Nanomedicine. 2023; 18:5265-5287.

PMID: 37746050 PMC: 10516212. DOI: 10.2147/IJN.S418259.


GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal axis.

Guo W, Gong Q, Zong X, Wu D, Li Y, Xiao H Exp Hematol Oncol. 2023; 12(1):15.

PMID: 36721229 PMC: 9887879. DOI: 10.1186/s40164-023-00376-4.


Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps.

Chen D, Liang H, Huang L, Zhou H, Wang Z FEBS Open Bio. 2022; 14(8):1365-1377.

PMID: 36271684 PMC: 11301266. DOI: 10.1002/2211-5463.13499.


Antimicrobial Step-Down Therapy versus Conventional Antimicrobial Therapy in the Treatment of Patients with Sepsis.

Peng Z, Niu Z, Zhang R, Pan L, Feng H, Zhou Y Dis Markers. 2022; 2022:3117805.

PMID: 36092959 PMC: 9452988. DOI: 10.1155/2022/3117805.

References
1.
Khan A, Slifer T, Araujo F, Remington J . Effect of quinupristin/dalfopristin on production of cytokines by human monocytes. J Infect Dis. 2000; 182(1):356-8. DOI: 10.1086/315655. View

2.
Wang X, Sun S, Duan Z, Yang C, Chu C, Wang K . Protective effect of ethyl pyruvate on gut barrier function through regulations of ROS-related NETs formation during sepsis. Mol Immunol. 2021; 132:108-116. DOI: 10.1016/j.molimm.2021.01.012. View

3.
Opal S, Laterre P, Francois B, LaRosa S, Angus D, Mira J . Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013; 309(11):1154-62. DOI: 10.1001/jama.2013.2194. View

4.
Bystrzycka W, Moskalik A, Sieczkowska S, Manda-Handzlik A, Demkow U, Ciepiela O . The effect of clindamycin and amoxicillin on neutrophil extracellular trap (NET) release. Cent Eur J Immunol. 2016; 41(1):1-5. PMC: 4829816. DOI: 10.5114/ceji.2016.58811. View

5.
Cheng S, Scicluna B, Arts R, Gresnigt M, Lachmandas E, Giamarellos-Bourboulis E . Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol. 2016; 17(4):406-13. DOI: 10.1038/ni.3398. View